Research Analysts’ Weekly Ratings Updates for Krystal Biotech (KRYS)

Several analysts have recently updated their ratings and price targets for Krystal Biotech (NASDAQ: KRYS):

• 5/18/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.
• 5/9/2026 – Krystal Biotech was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/5/2026 – Krystal Biotech had its “outperform” rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
• 5/5/2026 – Krystal Biotech had its price target raised by Citigroup Inc. from $371.00 to $378.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Krystal Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $310.00 price target on the stock.
• 4/9/2026 – Krystal Biotech was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 3/27/2026 – Krystal Biotech is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 3/25/2026 – Krystal Biotech was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer directly owned 22,366 shares of the company’s stock, valued at $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the transaction, the insider directly owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 116,664 shares of company stock valued at $31,136,828 over the last three months. 13.10% of the stock is currently owned by company insiders.

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.